
At-home tests offered to women to drive down cervical cancer cases
The tests, which can be performed at home, look for the human papillomavirus (HPV) – the virus which is linked to the majority of cases of cervical cancer.
After getting the nod from the UK National Screening Committee in March, the NHS in England is going to offer the tests to certain women.
It is expected that the rollout will begin in January next year.
The NHS offers cervical screening tests – previously known as smear tests – to all women aged 25-64 every three years.
But many people do not take up the offer, with a number citing a lack of time, discomfort or embarrassment.
Data published by the NHS last November showed five million women are not up to date with routine check-ups.
Now officials have said that at-home kits will be offered to women who have rarely or have never attended their cervical screening.
The initiative will see women sent a self-sampling kit in the post which can be returned via pre-paid mail.
People who were found to have the HPV virus will be encouraged to attend an in-person appointment with a clinician.
Research has suggested that offering DIY testing kits could boost uptake.
The YouScreen trial, which was led by King's College London in partnership with NHS England, found that offering self-sampling kits to 'under-screened' women when they attend their GP practice and by posting kits to women's homes could boost uptake in England by about 400,000 each year.
The Department of Health and Social Care said the new approach could potentially save about 5,000 lives a year across England.
It said that the new programme 'specifically targets those groups consistently missing vital appointments' including: younger women, those from minority ethnic backgrounds, people with disabilities and LGBT plus people.
Health and Social Care Secretary Wes Streeting said: 'These self-sampling kits represent healthcare that works around people's lives, not the other way around.
'They put women firmly in control of their own health, ensuring we catch more cancers at their earliest, most treatable stages.
'Our 10-year health plan will fundamentally reform the NHS, shifting focus from treating illness to preventing it before it starts.
'We know the earlier cancer is diagnosed the better the chances are of survival.
'By making screening more convenient, we're tackling the barriers that keep millions of women from potentially life-saving tests.'
Dr Anita Lim, chief investigator of the YouScreen trial from King's College London, added: 'This is a significant step forward for cervical cancer prevention and brings us closer to the NHS goal of eliminating the disease by 2040.
'The YouScreen trial, which provided self-sampling HPV kits to under-screen women in London, demonstrated that self-sampling could reach people who find it difficult to attend traditional screening – including those from diverse and underserved populations.
'It's hugely positive to see this now reflected in national policy, helping more people get protected from this highly preventable cancer.'
Michelle Kane, NHS England's director of screening, added: 'There are a number of reasons that stop some women taking up the offer of screening and we hope the introduction of self-testing will encourage more women to take up this life-saving test in a way that works for them.
'I'd encourage anyone who gets an invite for a cervical screening, either from their local GP practice or the NHS App, to attend and if you have any worrying symptoms, please contact your GP. It could save your life.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Western Telegraph
15 minutes ago
- Western Telegraph
Watchdog acted ‘irrationally' in registering private gender clinic, court told
Former nurse Susan Evans and a mother known as XX are taking legal action against the Care Quality Commission (CQC) over its decision to register the Gender Plus Hormone Clinic (GPHC) in January last year. The two are also challenging the regulator's decision to continue the clinic's registration and to allow it to prescribe cross-sex hormone treatment to 16 and 17-year-olds without conditions, made last December. The clinic, which was rated outstanding by the watchdog last year, treats people aged 16 and older, including through prescribing gender-affirming – masculinising or feminising – hormones, but, in line with the NHS, does not prescribe puberty blockers. At arriving at the conclusion that the provider should continue to be registered without any conditions … the CQC has acted irrationally Tom Cross KC Lawyers representing the two women told a hearing on Tuesday that the watchdog did not consider aspects that were 'obviously material' when making its decision, including the NHS's stance on hormone treatment for children aged 16 and 17 in light of the Cass Review. The watchdog is defending the claim, telling the court that it was 'abundantly clear that there was ample evidence' for its decision, while lawyers for the company which runs the clinic, Gender Plus Healthcare Limited, said the legal action was 'fatally flawed'. Opening the women's case on Tuesday, barrister Tom Cross KC said the clinic was believed to be the only hormone treatment provider to 16 and 17-year-olds in England, and that the claimants' concern was about safety, with Ms Evans previously stating she believed the registration 'creates a significant risk of a two-tier approach'. Susan Evans outside the Royal Courts of Justice ahead of the legal challenge (Callum Parke/PA) Mr Cross said: 'At arriving at the conclusion that the provider should continue to be registered without any conditions … the CQC has acted irrationally.' He added: 'It has not factored into its conclusion a number of aspects of the process on the NHS, informed by the Cass Review, which serve as important safeguards for children within the cohort and were obviously material.' The barrister said that had the CQC factored these in, it would have 'decided to exercise its power to halt the treatment' of under-18s, and that its decision was 'simply not open to them'. He claimed that 'at the very least' the court 'should require the CQC to think again about the adequacy of the safeguards'. Hormone treatment was previously provided on the NHS at the now-closed Gender Identity Development Service (Gids) run by the Tavistock and Portman NHS Foundation Trust, where Ms Evans previously worked. But a review published by Baroness Cass in April last year said that 'extreme caution' should be demonstrated when deciding to prescribe the treatment to 16 and 17-year-olds, and that there should be 'clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18'. The NHS has opened three specialist children's gender clinics and has plans for a further five covering the seven NHS regions in England by the end of 2026, but has said that all recommendations for hormone interventions must be endorsed by a national multi-disciplinary team (MDT). Dr Aidan Kelly, clinical psychologist and director of Gender Plus Hormone Clinic, outside the Royal Courts of Justice on Tuesday (Callum Parke/PA) It is understood that the MDT has not yet received any recommendations for hormone treatment for 16 and 17-year-olds, since the Cass Review. GPHC was set up by Dr Aidan Kelly and is led by nurse consultant Paul Carruthers, who both worked at Gids, and has previously said it primarily treats patients aged between 16 and 25, using its own MDT. But Mr Cross said in written submissions that in the year up to June 2024, GPHC has 'accepted almost every single patient that it considered' for hormone treatment, and that the contrast with the NHS 'could not be more stark'. He said there were 'a number of key differences' between GPHC and the NHS safeguards, including that referrals to the former came from Dr Kelly's company, Kelly Psychology, which is unregulated. In its professional judgment, it found that the provider was taking reasonable steps to safeguard 16 and 17-year-olds by way of its existing processes Jamie Burton KC He said: 'It is, and ought to have been, obvious that the unregulated nature of the referrer enhanced the risk of patient safety.' He concluded: 'Either the CQC had to impose a condition which rationally ensured patient safety, or, if that were not possible, had to decide not to continue the registration.' Jamie Burton KC, for the CQC, said that there was 'ample evidence' that Kelly Psychology 'did not pose an unacceptable risk' to patients, and that a 'significant number' of those assessed by the company were not referred for treatment at GPHC. The court was told that the CQC found no evidence of 'improper decision making or anything that might flag a concern', and that the clinic was found to be 'committed to the safety and best interests of its patients'. He continued: 'CQC found GHPC to be acting in line with national guidance, including the NHS England 2024 Criteria. 'It found nothing to suggest that this was merely lip service or that GPHC management held an ideological commitment that was undermining its professional and regulatory commitments, or otherwise threatening the safety of patients.' He also said that the CQC 'had regard' to NHS processes, and that there could not be 'any legitimate doubt about the correctness of the ultimate outcome, or GPHC's continued registration'. He said: 'In its professional judgment, it found that the provider was taking reasonable steps to safeguard 16 and 17-year-olds by way of its existing processes.' Peter Mant KC, for Gender Plus Healthcare Limited, said that there was no legal requirement for a private provider to mirror NHS care and that the claimants' concerns 'do not have a high-quality evidence base'. He continued that the clinic's model was 'entirely consistent' with the Cass Review and NHS policy, and that patients 'no longer routinely have any input' from Kelly Psychology. He added that concerns related to the rate of accepting new patients were 'unjustified', and that the court should not 'go behind' the CQC's decision. The hearing before Mrs Justice Eady is expected to conclude on Wednesday, with a judgment expected in writing at a later date.


Wales Online
44 minutes ago
- Wales Online
Former Sky News host Dermot Murnaghan diagnosed with stage four prostate cancer
Former Sky News host Dermot Murnaghan diagnosed with stage four prostate cancer The broadcaster, 67, who spent more than 15 years at the news channel before his departure in 2023, said he is "responding positively" to treatment in a post to X on Monday. He is supported by his family, alongside fans commenting under his original post discussing the diagnosis (Image: Getty Images Europe ) Former Sky News presenter Dermot Murnaghan has announced his diagnosis with stage four prostate cancer. The broadcaster, 67, who spent more than 15 years at the news channel before his departure in 2023, said he is "responding positively" to treatment in a post to X on Monday. "Some personal news... I've been diagnosed with Stage IV advanced prostate cancer", he said. "I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough – they are administering the best possible care with expertise, compassion and sensitivity. "I'm responding positively to their excellent treatment, and feeling well." Stage four prostate cancer can mean that the cancer has spread into different parts of the body including nearby body organs, such as the back passage or bladder, nearby lymph nodes and other parts of the body outside the pelvis, such as the bones, lungs or liver, according to the Cancer Research UK website. Article continues below "I'm blessed to be fortified by the monumental love and support of my wife, family and close friends", Murnaghan said. "Needless to say my message to all men over 50, in high risk groups, or displaying symptoms, is get yourself tested and campaign for routine prostate screening by the NHS." He also said that he is aiming to take part in Sir Chris Hoy's fundraising charity bike ride in September which will raise awareness and funds for cancer charities across the UK. The Olympian announced he had a terminal diagnosis for prostate cancer in October 2024. The Tour de 4 ride, which will begin and end at the Sir Chris Hoy velodrome in Glasgow on September 7, aims to change the perception of people living with stage four cancer. NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. About one in eight men will get prostate cancer in their lifetime, according to the charity Prostate Cancer UK, and the disease often has no symptoms in its earlier stages. Murnaghan presents true crime documentary series Killer Britain and the podcast Legends Of News. Before joining Sky News, Murnaghan presented ITV's News At Ten and the BBC Ten O'Clock News – now known as BBC News At Ten – as well as Channel 4 News. Article continues below Murnaghan also hosted the BBC's quiz programme Eggheads and presented Sky News At Ten and talk show Murnaghan before his last role at the channel as a newsreader on Sky News Tonight. During his time, he covered big events such as the announcement of the death of Queen Elizabeth II, the 2019 general election, the funeral of Prince Philip and the 2020 US presidential election.


Glasgow Times
an hour ago
- Glasgow Times
Give doctors work phones to tackle burnout and abuse, medics say
It comes as one doctor described using six apps on her personal device to do her job 'safely', and revealed the trust she works at relies on WhatsApp to fill locum shifts. Currently, there is no national NHS England policy that requires trusts to provide work phones to doctors or other staff. Delegates at the BMA's annual representative meeting in Liverpool voted for the union to demand employer-funded mobile phones for all medical staff to carry out NHS or university work, while rejecting any expectation that medics should use personal devices for professional communication. Dr Latifa Patel, chairwoman of the BMA's representative body and workforce lead, said: 'Many workplaces offer devices for professional communication, and the NHS should be no different. 'Doctors often work across the hospital site and in the community, including home visits, and need to be contactable. 'In recent years, we have seen an increasing reliance on doctors' own personal mobile phones.' BMA members also called for 'robust' safeguards to protect doctors from inappropriate contact, including sexual harassment, while advocating for clear boundaries between work life and personal life to reduce burnout. Dr Patel added: 'Using a work device, like a mobile phone, can help to define boundaries between work and home life, and significantly reduce burnout – something we know many doctors experience, and which is undoubtedly contributing to them either reducing their hours or leaving the NHS altogether. 'We also know some doctors are impacted by inappropriate contact, such as abuse or sexual harassment, sometimes in the form of unwanted messages and communication outside of work. 'Removing the reliance on personal devices is an action employers can take to mitigate these risks. 'We invite the Government to work with us to see how these devices can be introduced in the NHS as part of efforts to improve doctor wellbeing.' Emma Andrews told delegates she uses six different apps on her personal phone to do her job 'safely and to do it well'. She spoke of one incident where a medical team would not have been able to locate a patient in an 'obscure' room without using WhatsApp, with locum shifts in her trust also filled using the app. 'Before medicine, I was a civil servant, and I was provided with a phone, a laptop, because I needed it to do my job. 'It also provided security to the departments I worked in, so that government business only happened on government devices. 'Albeit it's not unreasonable to expect an employer to provide the tools I need to do my job. 'We shouldn't be subsidising the NHS with our data, with our battery life or with our work-life balance.'